secwatch.observer — SEC 8-K summary
======================================

Issuer:     PROKIDNEY CORP. (PROK)
CIK:        0001850270
Form:       8-K
Filed at:   2024-03-22T23:59:59+00:00
Accession:  0000950170-24-034961
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ProKidney FY2023 net loss $135.4M; cash $363M; positive Phase 2 data; mfg pause
-------------------------------------------------------------------------------

- Net loss before noncontrolling interest $135.4M vs $148.1M in 2022; cash $363.0M, funding into Q4 2025.
- R&D expenses $106.7M, up $24.6M on Phase 3 costs; G&A $44.8M, down $26.1M on lower equity comp.
- Appointed Dr. Bruce Culleton as CEO and Nikhil Pereira-Kamath as Chief Business Officer.
- Positive interim Phase 2 RMCL-002 data showed kidney function preservation; PROACT 1 enrollment modified to eGFR 20-35.
- Manufacturing paused for protocol amendment and QP audit; expects PROACT 1 and PROACT 2 enrollment to resume mid-2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1850270/000095017024034961/0000950170-24-034961-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1850270/000095017024034961/prok-20240321.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-034961

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer